Evivo with MCT Oil

Bifidobacterium longum subsp. infantis (B. infantis)

We activated it and named it Evivo activated B. infantis, EVC001, Actibif®. And that’s not the only transformation you’ll see.

Evivo (activated B. infantis EVC001, ActiBif®) transforms human milk oligosaccharides, or HMOs, to release nutrients for the infant and maximize the growth of beneficial bacteria—critical to building a healthy gut microbiome. Overall, the combination of feeding Evivo along with breast milk restores the infant gut microbiome to its original, natural state—the way it was before the unintended consequences of modern medical practices and lifestyles.

B. infantis EVC001.
The strain that matters.

The past several decades have seen a significant increase in infant gut dysbiosis, along with a rapid rise in the incidence of eczema, allergies, obesity, and diabetes.101533 Research indicates these two events may be related—and solving gut dysbiosis can make an impact.

However, choosing an effective probiotic for infant use requires selecting the right bacterial strain, in combination with the right food source, given at the right time in infant development.  Evivo® (activated B. infantis EVC001, Actibif®) in combination with human milk, is clinically proven to effectively reduce the abundance of potentially pathogenic bacteria, and provide functional, measurable benefits to the infant gut within days.

View this informative video from the International Scientific Association for Probiotics and Prebiotics (ISAPP) on differences in probiotic strain bacteria.

Breast Milk Composition diagram

Approximately 15% of the nutrients in breast milk are comprised of HMOs, which are completely indigestible by the infant and often excreted in the absence of specific gut bacteria.1 This results in a loss of nutrients for the baby. Importantly, human milk feeds both the infant and the microbiome, which converts HMOs into usable nutrients for the infant. Evivo is the only activated bacteria to utilize all indigestible HMOs in milk, and does so in a unique and superior manner that allows B. infantis to grow and dominate the gut. Over millions of years, B. infantis has evolved to:

  • bind and internalize the intact oligosaccharide 
  • utilize catabolic enzymes to break down the oligosaccharides structures
  • effectively metabolize the resulting monomers
B. infantis (bifidobacterium infantis) metabolizes HMOs intracellularly.

By sequestering the oligosaccharides intracellularly, B. infantis helps to prevent cross-feeding of other less desirable members of the microbiome. Evivo in partnership with human milk is the only probiotic clinically proven to reduce the relative abundance of less desirable microorganisms like E. coli and Clostridium.2 Other organisms, such as Bacteroides and Proteobacteria, are known to produce endotoxins and have been associated with an increased incidence of autoimmune disorders in term infants3 and NEC in newborns.4

Evivo is appropriate for use in infants delivered either vaginally or by C-section. Evivo is gentle on the digestive system and is clinically proven to improve an infant’s stool frequency and quality.5

Evivo (with Activated B. infantis) is a food that helps meet specific dietary needs of infants consuming breast milk as all or part of their diet. Evivo contains no artificial colors, dyes, flavors, or preservatives; is free of additives, and is gluten-free.

Evivo with B. infantis contains no artificial colors, dyes, flavors, or preservatives; is free of additives, and is gluten-free.

Get your patients started on Evivo.

Fight antibiotic resistance in your patients with the only clinically proven baby probiotic of its kind. Evivo.

Request more information

1. Smilowitz JT, Lebrilla CB, Mills DA et al. Breast milk oligosaccharides: structure-function relationships in the neonate. Annu Rev Nutr. 2014;34:143-169.
2. Data on file, Evolve BioSystems, Inc.
3. Vatanen T, Kostic AD, d’Hennezel E et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165(4):842-853.
4. Pammi M, Cope J, Tarr PI et al. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome. 2017;5(1):31.
5. Smilowitz JT, Moya J, Breck MA et al. Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial. BMC Pediatr. 2017;17(1):133. doi: 10.1186/s12887-017-0886-9.
6. Gura T. Nature’s first functional food. Science. 2014;345(6198):747-749.